Cybin Inc is a trailblazer in the biopharmaceutical industry, focusing on the development of psychedelic-based treatments. With a robust pipeline, including CYB003 for major depressive and alcohol use disorders, CYB004 for generalized anxiety, and CYB005 for neuroinflammation, Cybin is at the forefront of exploring the therapeutic potential of psychedelics. Additionally, its EMBARK model offers a unique psychological support framework, enhancing the healing process. Based in Toronto, Canada, Cybin is committed to unlocking new pathways to mental wellness.